Abstract
■ Interim data from the Phase II FITZROY study of lgotinib, a novel oral JAK1 selective inhibitor developed by Galapagos, showed that this agent induced clinical remission in patients with moderate to severe Crohn disease. Speci cally, the percentage of patients achieving a Crohn’s Disease Activity Index score lower than 150 was statistically signi cantly higher in patients treated with lgotinib compared with those receiving placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
